Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH stratified randomized induction therapy trial in recent-onset arthritis
NL-OMON23237Active, not recruiting
- Sponsor
- Erasmus MC Department of Rheumatology
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of methotrexate, 5-aminosalicylic acid + sulphasalazine, hydroxychloroquine, prednisone, naproxen and 1 more in rheumatoid arthritis (RA) and autoimmune arthritis (9 arms), sponsored by Erasmus MC Department of Rheumatology. Primary endpoints: Functional ability over time, Disease activity over time and 1 more. Started Jul 2007; status: active, not recruiting.
02
Drugs
methotrexate5-aminosalicylic acid + sulphasalazinehydroxychloroquineprednisonenaproxen
03
Conditions
rheumatoid arthritis (RA)autoimmune arthritis
Beyond the preview
Go deeper on NL-OMON23237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23237.